Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®. (19th March 2020)

• Record Type: Journal Article
• Authors: Schramm, Rene; Zittermann, Armin; Morshuis, Michiel; Schoenbrodt, Michael; von Roessing, Ellen; von Dossow, Vera; Koster, Andreas; Fox, Henrik; Hakim‐Meibodi, Kavous; Gummert, Jan F.
• Is Part Of: ESC heart failure. Volume 7:Number 3(2020)
• Page Start: 908
• Page End: 914
• Publication Date: 2020-03-19
• Subjects: Mechanical circulatory support -- Left ventricular assist device -- Centrifugal continuous flow pump; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12649
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Centrifugal continuous flow pumps are currently the state of the art in left ventricular assist device therapy. This study was conducted to compare the results after implantation of the HVAD® and the HeartMate 3®. Methods and results: We retrospectively analysed preoperative and post‐operative patient data of all 106 patients, who received a HeartMate 3 (HM3) at our centre between 2014 and 2018. A total of 392 patients receiving a sintered HVAD® served as controls. Patient matching was performed for age, sex, Interagency Registry for Mechanically Assisted Circulatory Support level at the time of implant, perioperative right heart failure, and implantation strategy, that is, bridge to transplant or destination therapy, as well as preoperative renal function, that is, as indicated by serum creatinine levels. A total of 79 matched pairs could be identified. During a median follow‐up of 15.3 months (range: 0–30 months), 23 (29.1%) and 19 (24.1%) patients died in the HVAD and HM3 groups, respectively, with a hazard ratio for mortality of 0.84 [95% confidence interval (CI): 0.46–1.54; P = 0.568]. Freedom from cerebrovascular events did not differ significantly between study groups, with a hazard ratio of 0.57 (95% CI: 0.23–1.45; P = 0.241). The risk of driveline infection was significantly lower in the HM3 ( n = 33) than in the HVAD ( n = 55) group (hazard ratio = 0.54; 95% CI: 0.35–0.84; P = 0.006). Eight HVAD, but no HM3, patients developed a pump thrombosis during follow‐up ( P = 0.148). Conclusions: Performance of both currently used centrifugal left ventricular assist device systems is comparable in terms of short‐term patient survival and freedom from cerebrovascular events. In our single‐centre experience, HM3 patients less frequently develop driveline infections and no pump thrombosis, which requires further evaluation.